3-Methylglutaconic acid

From WikiMD.com Medical Encyclopedia

3-Methylglutaconic Acid[edit | edit source]

Chemical structure of 3-Methylglutaconic acid

3-Methylglutaconic acid is an organic compound that is classified as a dicarboxylic acid. It is a derivative of glutaconic acid with a methyl group attached to the third carbon of the pentadiene chain. This compound is of particular interest in the field of biochemistry and medicine due to its role in certain metabolic disorders.

Structure and Properties[edit | edit source]

3-Methylglutaconic acid has the chemical formula C6H10O4. It consists of a five-carbon chain with two carboxylic acid groups and a methyl group attached to the third carbon. The presence of the methyl group distinguishes it from glutaconic acid.

The compound is typically found in its anionic form, 3-methylglutaconate, under physiological conditions. It is a colorless solid that is soluble in water and exhibits typical acidic properties.

Biological Role[edit | edit source]

In the human body, 3-methylglutaconic acid is an intermediate in the metabolism of certain amino acids, including leucine. It is produced in the mitochondria and is involved in the tricarboxylic acid cycle (TCA cycle), also known as the Krebs cycle.

Clinical Significance[edit | edit source]

Elevated levels of 3-methylglutaconic acid in the urine are associated with a group of metabolic disorders known as 3-methylglutaconic aciduria (3-MGA). These disorders are characterized by defects in mitochondrial function and can lead to a variety of symptoms, including developmental delay, muscle weakness, and neurological problems.

There are several types of 3-methylglutaconic aciduria, each with different genetic causes and clinical presentations. These include:

  • Type I: Caused by mutations in the AUH gene, which encodes an enzyme involved in leucine metabolism.
  • Type II (Barth syndrome): A rare X-linked disorder affecting mitochondrial function, often associated with cardiomyopathy and neutropenia.
  • Type III (Costeff syndrome): Characterized by optic atrophy and neurological symptoms, linked to mutations in the OPA3 gene.

Diagnosis and Treatment[edit | edit source]

Diagnosis of 3-methylglutaconic aciduria is typically made through urine organic acid analysis using gas chromatography-mass spectrometry (GC-MS). Genetic testing can confirm the specific type of the disorder.

Treatment is largely supportive and may include dietary management, physical therapy, and medications to manage symptoms. In some cases, coenzyme Q10 supplementation has been used to support mitochondrial function.

Related Pages[edit | edit source]




WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD